Summit Global Investments raised its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 86.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 415,558 shares of the company's stock after buying an additional 192,143 shares during the period. Summit Global Investments' holdings in Takeda Pharmaceutical were worth $5,909,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently modified their holdings of TAK. EverSource Wealth Advisors LLC lifted its holdings in Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock worth $43,000 after acquiring an additional 859 shares during the period. Headlands Technologies LLC purchased a new stake in Takeda Pharmaceutical during the second quarter valued at about $59,000. Hexagon Capital Partners LLC boosted its holdings in Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company's stock worth $63,000 after buying an additional 1,129 shares during the period. Blue Trust Inc. boosted its stake in Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company's stock worth $76,000 after purchasing an additional 2,330 shares during the period. Finally, Ridgewood Investments LLC bought a new position in shares of Takeda Pharmaceutical in the second quarter valued at approximately $89,000. Hedge funds and other institutional investors own 9.17% of the company's stock.
Takeda Pharmaceutical Price Performance
Shares of Takeda Pharmaceutical stock traded down $0.07 during trading on Friday, hitting $13.79. The stock had a trading volume of 683,310 shares, compared to its average volume of 1,828,286. The firm has a market cap of $43.88 billion, a price-to-earnings ratio of 23.90, a P/E/G ratio of 0.26 and a beta of 0.54. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The business's 50-day moving average is $14.42 and its 200 day moving average is $13.81. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
